Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer  

作用于骨基质的放射性药物在治疗骨转移前列腺癌中的潜在协同作用

作　　者：Oliver Sartor 

机构地区：[1]Departments of Medicine and Urology, Tulane Medical School, New Orleans, LA 70115, USA

出　　处：《Asian Journal of Andrology》2011年第3期366-368,510,共4页亚洲男性学杂志（英文版）

摘　　要：Genetic heterogeneity and chemotherapy-resistant ＇stem cells＇ represent two of the most pressing issues in devising new strategies for the treatment of advanced prostate cancer. Though curative strategies have long been present for men with localized disease, metastatic prostate cancer is currently incurable. Though substantial improvements in outcomes are now possible through the utilization of newly approved therapies, novel combinations are clearly needed. Herein we describe potentially synergistic interactions between bone stromal-targeted radiopharmaceuticals and other therapies for treatment of bone-metastatic prostate cancer. Radiation has long been known to synergize with cytotoxic chemotherapies and recent data also suggest the possibility of synergy when combining radiation and immune-based strategies. Combination therapies will be required to substantially improve survival for men with castrate-resistant metastatic prostate cancer and we hypothesize that bone-targeted radiopharmaceuticals will play an important role in this Drocess.Genetic heterogeneity and chemotherapy-resistant ＇stem cells＇ represent two of the most pressing issues in devising new strategies for the treatment of advanced prostate cancer. Though curative strategies have long been present for men with localized disease, metastatic prostate cancer is currently incurable. Though substantial improvements in outcomes are now possible through the utilization of newly approved therapies, novel combinations are clearly needed. Herein we describe potentially synergistic interactions between bone stromal-targeted radiopharmaceuticals and other therapies for treatment of bone-metastatic prostate cancer. Radiation has long been known to synergize with cytotoxic chemotherapies and recent data also suggest the possibility of synergy when combining radiation and immune-based strategies. Combination therapies will be required to substantially improve survival for men with castrate-resistant metastatic prostate cancer and we hypothesize that bone-targeted radiopharmaceuticals will play an important role in this Drocess.

关 键 词：BONE immunotherapy metastasis prostate cancer RADIOPHARMACEUTICALS RADIUM SAMARIUM stroma STRONTIUM XL-184 

分 类 号：R[医药卫生]